Table 1 General Characteristics of Cohort
Total | Urban and Regional Indigenous | Remote Indigenous | Non-Indigenous | |||||
|---|---|---|---|---|---|---|---|---|
n(%) | Average MBS Expenditure | n(%) | Average MBS Expenditure | n(%) | Average MBS Expenditure | n(%) | Average MBS Expenditure | |
Participants | 535a | $1,699 | 146 (27%) | $1,863 | 113 (21%) | $1,161 | 276 (52%) | $1,833 |
Age, mean (SD) | 63 (12.5) | NA | 57 (8.8) | NA | 55 (13.6) | NA | 70 (9.5) | NA |
Morbidly Obese | 52 (10%) | $1,310 | 27 (18%) | $1,519 | 9 (8%) | $637 | 16 (7%) | $1,336 |
Female | 193 (36.1%) | $1,833 | 56 (39%) | $1,932 | 49 (43%) | $1,284 | 88 (32%) | $2,075 |
Primary Healthcare Provider | ||||||||
Aboriginal Medical Service (AMS) | 266 (50%) | $1,580 | 136 (93%) | $1,901 | 113 (100%) | $1,161 | 17 (6%) | $1,805 |
Non-AMS | 269 (50%) | $1,816 | 10 (7%) | $1,346 | 0 (0%) | NA | 259 (94%) | $1,834 |
Geographical Classification | ||||||||
Urban | 356 (67%) | $1,878 | 102 (70%) | $1,979 | 0 (0%) | NA | 254 (92%) | $1,837 |
Regional | 64 (12%) | $1,625 | 44 (30%) | $1,594 | 0 (0%) | NA | 20 (7%) | $1,693 |
Remote and very Remote | 115 (21%) | $1,185 | 0 (0%) | NA | 113 (100%) | $1,161 | 2 (1%) | $2,565 |
CVD Risk Group | ||||||||
Primary Prevention, not on optimal therapy before the trial | 94 (18%) | $1,421 | 41 (28%) | $1,623 | 20 (18%) | $789 | 33 (12%) | $1,421 |
Primary Prevention, on optimal therapy before the trial | 108 (20%) | $1,601 | 22 (15%) | $1,980 | 39 (35%) | $959 | 47 (17%) | $1,957 |
Secondary Prevention, not on optimal therapy before the trial | 42 (8%) | $1,941 | 12 (8%) | $1,819 | 4 (4%) | $1,346 | 26 (9%) | $2,089 |
Secondary Prevention, on optimal therapy before the trial | 291 (54%) | $1,790 | 71 (49%) | $1,973 | 50 (44%) | $1,452 | 170 (62%) | $1,813 |
Highest Educational Attainment | ||||||||
Primary education or lower | 142 (27%) | $1,513 | 51 (35%) | $1,703 | 49 (43%) | $1,041 | 42 (15%) | $1,834 |
Secondary level | 247 (46%) | $1,742 | 56 (38%) | $1,844 | 44 (39%) | $1,236 | 147 (53%) | $1,855 |
Post-secondary | 146 (27%) | $1,807 | 39 (27%) | $2,099 | 20 (18%) | $1,288 | 87 (32%) | $1,795 |
Risk Score of primary prevention patients, mean (SD) | 18.7 (5.9) | NA | 19.2 (5.8) | NA | 18.3 (6.8) | NA | 18.6 (5.2) | NA |
Presence of COPD at baseline of trial | 45 (8%) | $2,130 | 23 (16%) | $2,146 | 5 (4%) | $2,405 | 17 (6%) | $2,027 |
Presence of diabetes at baseline of trial | 289 (54%) | $1,741 | 98 (67%) | $1,961 | 83 (73%) | $1,083 | 108 (39%) | $2,047 |
Presence of gout at baseline of trial | 109 (20%) | $2,054 | 30 (21%) | $2,139 | 14 (12%) | $1,340 | 65 (24%) | $2,169 |
Received polypill intervention | 272 (51%) | $1,708 | 69 (47%) | $2,052 | 59 (52%) | $1,161 | 144 (52%) | $1,766 |